Cover Image

Update on biomarkers in neuromyelitis optica

Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Melamed, Esther (Author) , Levy, Michael (Author) , Waters, Patrick J. (Author) , Sato, Douglas Kazutoshi (Author) , Bennett, Jeffrey L. (Author) , John, Gareth R. (Author) , Hooper, Douglas C. (Author) , Saiz, Albert (Author) , Bar-Or, Amit (Author) , Kim, Ho Jin (Author) , Pandit, Lakha (Author) , Leite, Maria Isabel (Author) , Asgari, Nasrin (Author) , Kissani, Najib (Author) , Hintzen, Rogier (Author) , Marignier, Romain (Author) , Jarius, Sven (Author) , Marcelletti, John (Author) , Smith, Terry J. (Author) , Yeaman, Michael R. (Author) , Han, May H. (Author)
Format: Article (Journal)
Language:English
Published: July 23, 2015
In: Neurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology
Year: 2015, Volume: 2, Issue: 4
ISSN:2332-7812
DOI:10.1212/NXI.0000000000000134
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1212/NXI.0000000000000134
Verlag, lizenzpflichtig, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516398/
Get full text
Author Notes:Esther Melamed, MD, PhD, Michael Levy, MD, PhD, Patrick J. Waters, PhD, Douglas Kazutoshi Sato,MD, PhD, Jeffrey L. Bennett, MD, PhD, Gareth R. John, PhD, Douglas C. Hooper, PhD, Albert Saiz, MDAmit Bar-Or, MD, PhD, Ho Jin Kim, MD, Lakha Pandit, MD, Maria Isabel Leite, MD,DPhil, Nasrin Asgari, MD, PhD, Najib Kissani, MD, Rogier Hintzen, MD, PhD, Romain Marignier, MD, Sven Jarius, MD, John Marcelletti, PhD, Terry J. Smith, MD, Michael R. Yeaman, PhD, May H. Han, MD, On behalf of the GJCF-ICC&BR
Description
Summary:Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.
Item Description:Gesehen am 12.06.2020
Physical Description:Online Resource
ISSN:2332-7812
DOI:10.1212/NXI.0000000000000134

Similar Items